selected publications
- Changing Role of Adjuvant Therapy in Stage III Melanoma. The New England journal of medicine. 2025 Editorial Article GET IT
- Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study. Melanoma research. 2025 Academic Article GET IT
-
A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
2024
Academic Article
GET IT
Times cited: 6 -
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2024
Academic Article
GET IT
Times cited: 6 - A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease. Cancer journal (Sudbury, Mass.). 2024 Information Resource GET IT
-
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
Cancer research communications.
2023
Academic Article
GET IT
Times cited: 7 -
Management of immune-related cutaneous adverse events with dupilumab.
Journal for immunotherapy of cancer.
2023
Academic Article
GET IT
Times cited: 44 -
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Pigment cell & melanoma research.
2023
Academic Article
GET IT
Times cited: 1 -
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
The oncologist.
2023
Academic Article
GET IT
Times cited: 12 -
PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022
Editorial Article
GET IT
Times cited: 13 -
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Journal for immunotherapy of cancer.
2022
Academic Article
GET IT
Times cited: 43 -
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Academic Article
GET IT
Times cited: 46 -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Journal for immunotherapy of cancer.
2021
Information Resource
GET IT
Times cited: 13 -
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Science translational medicine.
2021
Academic Article
GET IT
Times cited: 86 -
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Editorial Article
GET IT
Times cited: 7 -
Time to publication of oncology trials and why some trials are never published.
PloS one.
2017
Academic Article
GET IT
Times cited: 26 - Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. Journal of translational medicine. 2016 Academic Article GET IT